BGM Group (NASDAQ:BGM) Trading Up 6.3% – What’s Next?

BGM Group Ltd. (NASDAQ:BGM) shares were up 6.3% on Tuesday . The company traded as high as $0.3629 and last traded at $0.3401. Approximately 296,371 shares were traded during mid-day trading, a decline of 29% from the average daily volume of 419,803 shares. The stock had previously closed at $0.3199.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d)” rating on shares of BGM Group in a research report on Monday, April 20th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

BGM Group Stock Performance

The business has a 50-day moving average price of $0.32 and a 200 day moving average price of $2.16.

Institutional Investors Weigh In On BGM Group

Institutional investors and hedge funds have recently modified their holdings of the stock. Marshall Wace LLP acquired a new stake in shares of BGM Group during the 2nd quarter valued at $218,000. Mariner LLC acquired a new stake in shares of BGM Group during the 3rd quarter valued at $267,000. Finally, Geode Capital Management LLC acquired a new stake in shares of BGM Group during the 2nd quarter valued at $412,000.

BGM Group Company Profile

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions.